NAOV
vs
S&P 500
NAOV
S&P 500
Over the past 12 months, NAOV has underperformed S&P 500, delivering a return of -94% compared to the S&P 500's +14% growth.
Stocks Performance
NAOV vs S&P 500
Performance Gap
NAOV vs S&P 500
Performance By Year
NAOV vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Nanovibronix Inc
Glance View
NanoVibronix, Inc. engages in the development of noninvasive biological response-activating devices. The company is headquartered in Elmsford, New York and currently employs 12 full-time employees. The company went IPO on 2015-04-24. The firm is focused on developing noninvasive biological response-activating devices utilizing its low intensity surface acoustic wave (SAW) technology, which targets biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products, which are in various stages of clinical and market development consist of UroShield, PainShield and WoundShield. Its PainShield family of products include PainShield MD, PainShield Plus and PainShield Relief. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low frequency, low intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. Its wholly owned subsidiary is NanoVibronix Ltd.
